London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.
The full publication is available online and can be viewed here